학술논문
Clinical features and oncological outcomes of bladder cancer microsatellite instability.
Document Type
Academic Journal
Author
Nagakawa S; Department of Urology, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan.; Shiota M; Department of Urology, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan.; Takamatsu D; Department of Urology, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan.; Department of Anatomic Pathology, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan.; Tsukahara S; Department of Urology, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan.; Mastumoto T; Department of Urology, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan.; Blas L; Department of Urology, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan.; Inokuchi J; Department of Urology, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan.; Oda Y; Department of Anatomic Pathology, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan.; Eto M; Department of Urology, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan.
Source
Publisher: Blackwell Science Asia Country of Publication: Australia NLM ID: 9440237 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1442-2042 (Electronic) Linking ISSN: 09198172 NLM ISO Abbreviation: Int J Urol Subsets: MEDLINE
Subject
Language
English
Abstract
Objectives: Excellent anticancer effect for solid tumors with microsatellite instability (MSI)-high by anti-PD-1 antibody has been reported. In this study, we investigated the clinical impact of MSI status in bladder cancer.
Methods: This study included 205 Japanese patients who underwent transurethral resection for bladder cancer between 2005 and 2021. The prevalence rates of microsatellite stable (MSS), MSI-low (MSI-L), and MSI-high (MSI-H) were determined using molecular testing. We examined the association of MSI status (MSS versus MSI-L/H) with clinicopathological characteristics and oncological outcomes.
Results: MSI-L/H tumors were associated with higher T-category in non-muscle invasive bladder cancer (NMIBC). Additionally, MSI-L/H tumors were associated with a higher risk of intravesical recurrence in NMIBC patients treated with intravesical bacillus Calmette-Guérin (BCG) but not with non-BCG therapy.
Conclusions: This study suggested that the MSI status might serve as a predictive marker for intravesical recurrence after BCG intravesical therapy in NMIBC and highlighted an unmet need for an alternative treatment in patients with MSI-L/H tumors.
(© 2024 The Japanese Urological Association.)
Methods: This study included 205 Japanese patients who underwent transurethral resection for bladder cancer between 2005 and 2021. The prevalence rates of microsatellite stable (MSS), MSI-low (MSI-L), and MSI-high (MSI-H) were determined using molecular testing. We examined the association of MSI status (MSS versus MSI-L/H) with clinicopathological characteristics and oncological outcomes.
Results: MSI-L/H tumors were associated with higher T-category in non-muscle invasive bladder cancer (NMIBC). Additionally, MSI-L/H tumors were associated with a higher risk of intravesical recurrence in NMIBC patients treated with intravesical bacillus Calmette-Guérin (BCG) but not with non-BCG therapy.
Conclusions: This study suggested that the MSI status might serve as a predictive marker for intravesical recurrence after BCG intravesical therapy in NMIBC and highlighted an unmet need for an alternative treatment in patients with MSI-L/H tumors.
(© 2024 The Japanese Urological Association.)